What injectable therapy is recommended for cholesterol management in an adult who requires additional LDL‑cholesterol lowering despite maximally tolerated statin therapy or who cannot tolerate statins?

Injectable Therapy for Cholesterol Management

PCSK9 inhibitors (evolocumab or alirocumab) are the recommended injectable therapies for adults requiring additional LDL-cholesterol lowering despite maximally tolerated statin therapy or who cannot tolerate statins, particularly in those at high or very high cardiovascular risk. 1

Risk-Stratified Approach to Injectable Therapy

Very High-Risk Patients (Secondary Prevention)

For patients with clinical atherosclerotic cardiovascular disease at very high risk, PCSK9 monoclonal antibodies should be strongly considered when LDL-C remains ≥55 mg/dL despite maximally tolerated statin and ezetimibe therapy. 1

The stepwise algorithm is:

• First step: Add ezetimibe to maximally tolerated statin when LDL-C remains ≥70 mg/dL (1.8 mmol/L) 1
• Second step: Add PCSK9 inhibitor (evolocumab or alirocumab) when LDL-C remains ≥100 mg/dL (2.6 mmol/L) on statin plus ezetimibe 1
• Alternative approach: For patients requiring rapid LDL-C reduction >50%, simultaneous addition of ezetimibe and PCSK9 inhibitor to statin therapy may be reasonable 1

High-Risk Patients (Primary Prevention)

In high-risk primary prevention patients, PCSK9 inhibitors may be considered when LDL-C remains elevated despite maximally tolerated statin therapy, though the recommendation strength is weaker than for secondary prevention. 1

• European guidelines give this a Class IIb recommendation (Level C evidence) for primary prevention versus Class I (Level A) for secondary prevention 1

Choice of PCSK9 Inhibitor

PCSK9 monoclonal antibodies (evolocumab or alirocumab) are preferred as the initial injectable therapy due to demonstrated cardiovascular outcomes benefits in major trials (FOURIER and ODYSSEY Outcomes). 1, 2

Inclisiran as Alternative

Inclisiran (siRNA-based PCSK9 inhibitor) may be considered in specific circumstances: 1

• Patients with demonstrated poor adherence to PCSK9 monoclonal antibodies
• Adverse effects from both evolocumab and alirocumab
• Patients unable to self-inject (inclisiran requires only twice-yearly dosing after initial loading)

Important caveat: Do not combine PCSK9 monoclonal antibodies with inclisiran—use inclisiran as a replacement, not an addition, as there is no evidence for additional benefit from combination therapy 1

Expected Efficacy and Safety

LDL-C Reduction

PCSK9 inhibitors reduce LDL-C by approximately 50-62% when added to statin therapy. 2, 3

• Alirocumab demonstrated a 62 percentage point greater reduction versus placebo at 24 weeks, with sustained effect through 78 weeks 2
• Inclisiran reduces LDL-C by approximately 50% 4

Cardiovascular Outcomes

PCSK9 monoclonal antibodies reduce major adverse cardiovascular events, with a post-hoc analysis showing a 48% relative risk reduction (HR 0.52) in the ODYSSEY LONG TERM trial. 2

Safety Profile

PCSK9 inhibitors have an excellent safety profile with no increased risk of muscle symptoms or new-onset diabetes. 3, 5

Common but generally mild adverse effects include:

• Injection-site reactions (5.9% vs 4.2% placebo) 2, 3
• Myalgia (5.4% vs 2.9% placebo) 2
• Neurocognitive events (1.2% vs 0.5% placebo) 2
• Ophthalmologic events (2.9% vs 1.9% placebo) 2

These injection-site reactions are typically mild to moderate in intensity and do not require discontinuation. 3, 5

Statin-Intolerant Patients

For patients who cannot tolerate any statin therapy, PCSK9 inhibitors can be used as monotherapy or in combination with ezetimibe, particularly in those with familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease. 1

• NICE guidelines specifically approve PCSK9 inhibitors for statin-intolerant patients with LDL-C ≥135 mg/dL (3.5 mmol/L) at very high cardiovascular risk 1

Common Pitfalls to Avoid

Do not use PCSK9 inhibitors in low cardiovascular risk patients—guidelines strongly recommend against adding these therapies when the burden outweighs minimal benefits. 1

Ensure patients have been on maximally tolerated statin therapy (not just any statin dose) before adding injectable therapy. 1

Verify that ezetimibe has been tried first in most cases before advancing to PCSK9 inhibitors, as this is more cost-effective and follows the stepwise approach endorsed by multiple guidelines. 1

Monitor adherence and lifestyle modifications before escalating therapy—poor adherence to existing medications should be addressed first. 1